Related Experiment Videos

Psoriasiform lesions on trunk and palms

Jennifer Clay Cather¹, John Christian Cather, M Alan Menter

¹Division of Dermatology, Department of Internal Medicine, Baylor University Medical Center, Dallas, Texas, USA.

Proceedings (Baylor University. Medical Center)

|November 10, 2005

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.

Dermatology and therapy·2022

Ixekizumab for the treatment of pediatric patients with moderate to severe plaque psoriasis.

Expert opinion on biological therapy·2021

Erythema Ab Igne and Malignant Transformation to Squamous Cell Carcinoma.

Cutis·2021

Tildrakizumab efficacy, drug survival, and safety are comparable in patients with psoriasis with and without metabolic syndrome: Long-term results from 2 phase 3 randomized controlled studies (reSURFACE 1 and reSURFACE 2).

Journal of the American Academy of Dermatology·2020

The Effect of Tildrakizumab on Cardiometabolic Risk Factors in Psoriasis by Metabolic Syndrome Status: Post Hoc Analysis of Two Phase 3 Trials (ReSURFACE 1 and ReSURFACE 2).

Journal of drugs in dermatology : JDD·2020

Cannabidiol primer for healthcare professionals.

Proceedings (Baylor University. Medical Center)·2020

See all related articles